


CHAPTER Health/Medical	CHAPTER 03	SECTION 001	SUBJECT 60
SECTION Drugs and Medications		DESCRIPTION Vivitrol® for Medication Assisted Treatment for Alcohol Use Disorders	
WRITTEN BY Stephanie Rudow, LMSW, CAADC, CCS Sarah Steinacker, D.O. Medical Director	REVISED BY Sarah Whitehead, RN Nursing Supervisor	AUTHORIZED BY  Lauren Emmons, ACSW CEO	

APPLICATION:

<input checked="" type="checkbox"/> CMH Staff	<input type="checkbox"/> Board Members	<input checked="" type="checkbox"/> Provider Network	<input checked="" type="checkbox"/> Employment Services Providers
<input type="checkbox"/> Employment Services Provider Agencies	<input checked="" type="checkbox"/> Independent Contractors	<input checked="" type="checkbox"/> Students	<input checked="" type="checkbox"/> Interns
<input checked="" type="checkbox"/> Volunteers	<input checked="" type="checkbox"/> Persons Served		

POLICY:

Vivitrol® (extended-release naltrexone injectable suspension) is a Medication Assisted Treatment (MAT) indicated for Alcohol Use Disorder (AUD). Lapeer County Community Mental Health (LCCMH) will offer Vivitrol® treatment to persons served with AUD.

STANDARDS:

- A. LCCMH will administer Vivitrol® in accordance with federal and state guidelines for medication for addiction treatment.
- B. Prescribers and nursing staff administering Vivitrol® will receive approved training prior to use.
- C. Vivitrol® will be stored according to manufacturer guidelines and dispensed to LCCMH by the onsite pharmacy.
- D. Vivitrol® will be used in conjunction with Co-Occurring Disorder Services at LCCMH for persons with AUD, as part of a comprehensive management program which includes psychosocial supports.

CHAPTER Health/Medical	CHAPTER 03	SECTION 001	SUBJECT 60
SECTION Drugs and Medications		DESCRIPTION Vivitrol® for Medication Assisted Treatment for Alcohol Use Disorder	

- E. A pre-administration screening, including labs and a physical examination for eligibility based on the package insert, is required before prescribing Vivitrol®.
- F. Persons served must have an orientation to medication for addiction treatment. The orientation must be documented in the electronic health record (EHR) before administering the medication.
- G. Persons served must be notified of possible side effects, including but not limited to:
 - 1. Increased risk of opioid overdose due to loss of tolerance
 - 2. Injection site reactions
 - 3. Precipitated opioid withdrawal
 - 4. Risk of liver damage
- H. Persons served will sign a treatment agreement prior to administration of Vivitrol® indicating they must remain engaged with their case holder at LCCMH to continue to receive the medication.
- I. Because Vivitrol® can precipitate opioid withdrawal in active opioid users, persons served will be screened for underlying opioid dependence or recent use of opioids. Persons served must be opioid-free for at least 7-10 days or longer before Vivitrol® can be administered.

PROCEDURES:

- A. The Co-Occurring Disorder Services Treatment Team will identify persons served who would benefit from medication for addiction treatment.
- B. MAT will be discussed between the prescriber, Co-Occurring Disorder Services staff, and person served.
- C. Orientation to Vivitrol® is conducted by the Co-Occurring Disorder Services Staff for persons served who are interested in MAT for AUD. Persons served who complete orientation and want MAT must sign an agreement for treatment. The agreement will be scanned into the EHR.

CHAPTER Health/Medical	CHAPTER 03	SECTION 001	SUBJECT 60
SECTION Drugs and Medications		DESCRIPTION Vivitrol® for Medication Assisted Treatment for Alcohol Use Disorder	

- D. A physical screening for eligibility is scheduled and conducted by the LCCMH prescriber and nursing staff which includes:
1. Substance used-focused history and indications for use of MAT
 2. Reviewing all medication opioids for treatment of alcohol use disorder
 3. Baseline physical examination
 4. Review of contraindications and precautions/warnings
 5. Urine Drug Screen and alcohol screen
 6. Urine beta-HCG (human chorionic gonadotropin) pregnancy test for females
 7. Baseline labs for including: hepatitis panel acute with reflex and comprehensive metabolic panel (CMP).
- E. An appointment is scheduled for the Vivitrol® injection.
- F. Vivitrol® is administered by LCCMH Nursing Staff intramuscularly as a gluteal (buttocks) injection, using aseptic techniques according to the packaging insert.
- G. Persons served with elevated liver enzymes three (3) times higher than normal will be referred to their primary care physician. Persons served with Hepatitis B surface antigen positive, or Hepatitis C viral load will also be referred to their primary care physician, a gastroenterologist or infectious disease specialist.
- H. Vivitrol® will be discontinued if labs show aspartate transaminase (AST) / alanine transaminase (ALT) over five (5) times the upper limit of normal.
- I. Succeeding Vivitrol® injections are scheduled monthly or every four (4) weeks. In some cases, as determined by the prescriber, injections may be every 21 days or oral naltrexone may be added if the person served experiences cravings prior to the next scheduled injection.
- J. The Co-Occurring Disorder Services case holder attends follow-up appointments between the prescriber and persons served, at the request of the prescriber

CHAPTER Health/Medical	CHAPTER 03	SECTION 001	SUBJECT 60
SECTION Drugs and Medications		DESCRIPTION Vivitrol® for Medication Assisted Treatment for Alcohol Use Disorder	

- K. Persons served will continue with Co-Occurring Disorder Services treatment at LCCMH between injections.
- L. Prescribers and staff administering Vivitrol® injections will monitor for side effects.
- M. Injection site reactions that develop and signs of allergic reaction must be reported to the physician immediately and persons served will be sent to the nearest emergency room. LCCMH staff will complete an incident report and follow procedures in the Medication Errors Policy 03.001.15.

DEFINITIONS:

Alanine aminotransferase (ALT): Liver function test / blood test used to help detect, diagnose and monitor liver disease or damage.

Aspartate aminotransferase (AST): Liver function test / blood test used to help detect, diagnose and monitor liver disease or damage.

Co-Occurring Disorder: Having both a mental health diagnosis and a substance use disorder diagnosis.

Medication for addiction Treatment (MAT): The use of medications to treat substance use disorder and reduce craving, reduce days of drinking and reduce days of heavy drinking, in combination with counseling and behavioral therapies, to provide a whole-person approach to treatment of substance use disorders. (SAMHSA.gov)

Vivitrol®: Extended-release naltrexone, an opioid antagonist FDA approved for those 18 and older with alcohol use disorder or opioid use disorder.

REFERENCES:

<https://www.vivitrol.com/>

Incorporating Alcohol Pharmacotherapies into Medical Practice: A Treatment Improvement Protocol Tip 49 (samhsa.gov)

Interpretation of Hepatitis B serologic test results:
<https://www.cdc.gov/hepatitis/hbv/pdfs/serologicchartv8.pdf>

Medication for the Treatment of Alcohol Use Disorder: A Brief Guide (samhsa.gov)

CHAPTER Health/Medical	CHAPTER 03	SECTION 001	SUBJECT 60
SECTION Drugs and Medications		DESCRIPTION Vivitrol® for Medication Assisted Treatment for Alcohol Use Disorder	

SAMHSA guide medication for AUD:

<https://store.samhsa.gov/sites/default/files/d7/priv/sma15-4907.pdf>

SR:mgr